Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 23Carcinoma, Non-Small-Cell Lung 23Head and Neck Neoplasms 13Pancreatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Squamous Cell 8Neoplasms 7Lung Neoplasms 7Colonic Neoplasms 7Rectal Neoplasms 6Esophageal Neoplasms 5Carcinoma 5Recurrence 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Neoplasms, Squamous Cell 3Hereditary Sensory and Autonomic Neuropathies 3Glioblastoma 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colorectal Cancer Metastatic 3Breast Neoplasms 3Tongue Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Melanoma 2Glioma 2

Interventions

Gemcitabine 3ensituximab 1Lead 1Immunotherapy, Adoptive 1Cetuximab 1Bevacizumab 1Atu027 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Pancreatic Ductal × Cetuximab × Clear all
NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
1,130 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡